Effect of Huashi Runzao Prescription on Primary Sjögren's Syndrome
10.13422/j.cnki.syfjx.20231593
- VernacularTitle:化湿润燥方治疗原发性干燥综合征的临床疗效
- Author:
Zihua WU
1
;
Ziwei HUANG
1
;
Jiaqi CHEN
1
;
Qian HE
1
;
Jianying YANG
1
;
Yan ZHANG
1
;
Jiahe LIAO
1
;
Xinbo YU
1
;
Jing LUO
2
;
Qingwen TAO
2
Author Information
1. Beijing University of Chinese Medicine，Beijing 100029，China
2. Beijing Key Laboratory of Immune Inflammatory Disease， China-Japan Friendship Hospital，Beijing 100029，China
- Publication Type:Journal Article
- Keywords:
Sjögren's syndrome;
Zaobi;
combined dampness and dryness pattern;
resolving dampness and moistening dryness;
treatment;
Huashi Runzao prescription
- From:
Chinese Journal of Experimental Traditional Medical Formulae
2023;29(8):45-51
- CountryChina
- Language:Chinese
-
Abstract:
ObjectiveTo observe the efficacy and safety of Huashi Runzao prescription for patients with primary Sjögren's syndrome （pSS） of combined dryness and dampness pattern. MethodA total of 105 eligible patients were randomized into the experimental group （65 cases） and control group （40 cases）， and they were respectively treated with Huashi Runzao prescription and hydroxychloroquine for 12 weeks. Visual Analogue Scale （VAS） was employed to assess the symptoms. The symptoms of dryness， fatigue， and pain， European League Against Rheumatism （EULAR） Sjögren's Syndrome Patient Reported Index （ESSPRI）， EULAR Sjögren's syndrome disease activity index （ESSDAI）， and immune inflammatory indicators before and after treatment were compared between the two groups， and adverse reactions were observed. ResultAfter treatment， the ESSPRI score was lower than that before treatment in the experimental groups （P<0.01） and was lower in the experimental group than in the control group （P<0.05）. The VAS scores of dry mouth， dry eyes， overall dryness， fatigue， and pain in the experimental group decreased compared with those before treatment （P<0.01）， and the experimental group had lower VAS scores of dry mouth and overall dryness than the control group （P<0.01）. After treatment， the ESSDAI score of both groups decreased compared with that before treatment （P<0.05， P<0.01）， but there was no significant difference between the groups. After treatment， the level of immunoglobulin M （IgM） decreased （P<0.01） and the level of complement C3 increased （P<0.01） in the experimental group， while the level of complement C3 decreased in the control group （P<0.05）. There was no significant difference in the laboratory indexes between groups. During the treatment， stomachache occurred to one case in the experimental group， which was alleviated after the treatment， and no adverse reaction was observed in the control group. According to the chi-square test， the occurrence of adverse reactions was insignificantly different between the two groups. ConclusionHuashi Runzao prescription can alleviate the symptoms of dryness， fatigue， and pain， and reduce disease activity without associated side effects in pSS patients with combined dampness and dryness pattern.
